Aralez Pharma (ARLZ) Posts Wider Q4 Loss, Revenues Beat

Aralez Pharma (NASDAQ: ARLZ) reported Q4 EPS of ($0.68), $0.36 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $28 million versus the consensus estimate of $25.6 million.

GUIDANCE:

Aralez Pharma sees FY2018 revenue of $140-160 million, versus the consensus of $141.9 million.

For earnings history and earnings-related data on Aralez Pharma (ARLZ) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c